Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
National Institutes of Health · Opportunity PAR-25-321
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities
- Native American tribal organizations (other)
- Nonprofits with 501(c)(3), other than higher education
- Nonprofits without 501(c)(3)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
About this opportunity
Through this engineering-oriented Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.
Award history — this exact opportunity
NIH RePORTER lists 3 funded awards under PAR-25-321 across 3 organizations.
Total award obligations, not per-year amounts.
Recent awardees include: GEORGIA INSTITUTE OF TECHNOLOGY, J. DAVID GLADSTONE INSTITUTES, UNIVERSITY OF CALIFORNIA, SAN DIEGO.
Source: NIH RePORTER, matched on the exact opportunity number. NIH publishes success rates by institute and activity code — source.
Portfolio context — this listing covers more than this opportunity
This opportunity is funded under Assistance Listing 93.393 (“Cancer Cause and Prevention Research”), a broad federal program that made about 318 new awards per year over the last five fiscal years (median award $1.1M). Those figures describe that whole portfolio — not this specific solicitation, so we don't show them as if they were this opportunity's track record.
Applicant counts per solicitation are not published by any federal agency — no one can honestly sell you that number. NIH publishes success rates by institute and activity code — source.
Don't want to hunt for grants like this one? Get free deadline alerts for your state and focus areas.
Consultant or grant writer? See the client-ready Opportunity Brief for this grant — actual award sizes vs. the advertised ceiling, who wins, printable "prepared for your client" version.
Similar grants still open
| Opportunity | Agency | Deadline | Award ceiling | Eligible |
|---|---|---|---|---|
| Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required) | National Institutes of Health | September 25, 2026 16d left | — | Nonprofits |
| National Cancer Institute Youth Enjoy Science Research Education Program (R25 Clinical Trial Not Allowed) | National Institutes of Health | September 28, 2026 19d left | $400k | Nonprofits |
| NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed) | National Institutes of Health | October 14, 2026 35d left | — | Nonprofits |
| NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required) | National Institutes of Health | October 14, 2026 35d left | — | Nonprofits |